RxDoctor Payments Data

Tina Harrison, MD

Internal Medicine · Noblesville, INNPI 1285642629

Payments from drug & device makers

$790in general payments, 2019–2025

Across 42 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$252
  • Pfizer$94
  • Novo Nordisk$79
  • Lilly USA, LLC$74
  • Amgen$73
  • AstraZeneca$46
  • plus $170 from 8 others

What the payments were for

  • Food & beverage$790100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$790 in reported general payments places this provider in the 70th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$17,495
Medicare patients
107
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$32,875
TrulicityDulaglutide16$18,055
OzempicSemaglutide11$17,636
ShingrixVaricella-Zoster Ge/As01b/Pf11$2,375
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$2,276
Atorvastatin Calcium219$2,106
Levothyroxine Sodium159$1,023
SynthroidLevothyroxine Sodium12$957
Omeprazole42$932
Rosuvastatin Calcium102$847
Pen NeedlesPen Needle, Diabetic11$823
Metoprolol Succinate63$710
Duloxetine Hcl36$704
Gabapentin42$701
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide18$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$74$50,93042 claims
Novo NordiskOzempic$79$17,63611 claims
AbbVieSynthroid$252$95712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Noblesville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →